A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples

Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients

“…These results are in agreement with the findings of Goulding et al (1995) and confirm that highly significant clinical information can be obtained from the determination of ER using an immunohistochemical evaluation. Whatever scoring method is used, in this study we show that immunohistochemistry gives superior results to the cytosol assay as it is more closely related to patient outcome.…”

“…There are several published studies in which this has been done and they show generally good agreement between the overall findings with the two methods (Andersen et al, 1990;Saccani Jotti et al, 1994). Early studies using the immunohistochemical assay on fixed tissue sections suggest that the results are clinically relevant (Goulding et al, 1995;Veronese et al, 1995). However, there is no general agreement as to how the immunohistochemical assay should be evaluated and several different methods for scoring sections have been described (Kinsel et al, 1989;Remmele and Stegner, 1987;Reiner et al, 1990).…”

Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts

“…There was a Anti-GnRH Ab 1 90 ± 0 175 ± 5 < 5 2.5 ± 2.5 2 95 ± 5 205 ± 27 < 5 0 3 100 ± 0 180 ± 0 < 5 0 Tamoxifen 1 0 0 22 ± 8 47 ± 18 2 58 ± 34 95 ± 64 26 ± 2 53 ± 4 3 70 ± 10 65 ± 15 5 ± 0 10 ± 0 Placebo 1 60 ± 10 75 ± 25 25 ± 10 52 ± 22 2 87 ± 5 147 ± 33 < 5 8 ± 11 3 100 ± 0 175 ± 5 < 5 0 E 2 1 0 0 70 ± 0 120 ± 0 ER and PR expression was evaluated semi-quantitatively by immunocytochemical methods using receptor-specific monoclonal antibodies. The % of cells staining positive for each receptor and the H-scores derived by taking into account the intensity of staining (Goulding et al, 1995) similar trend in experiment 1 (Figure 1), where one animal treated with tamoxifen showed complete regression of tumour growth. There was no difference between tamoxifen and placebo groups in experiment 3 (Figure 3) during the 3 weeks before any mice were terminated.…”

“…Tumour sections were scored for percentage of cells staining for ER (or PR) and for the intensity of the staining. Histochemical scores (H-scores) were calculated from these two values as previously described (Goulding et al, 1995).…”

Antigen Retrieval Immunohistochemistry: Past, Present, and Future

“…They concluded that wild-type p53 may be detectable in normal cells after using AR, and pointed out the importance of technical conditions as well as the evaluation of normal tissue controls in the clinical application of p53 immunostaining. Goulding et al (1995) performed a comparative study based on two MAbs to ER, 1D5 (Dako) and H222 (Abbott; N ); pH 6, 100C, 10 min ( E,O ); pH 6, 90C, 10 min ( F,P ); pH 10, 100C, 20 min ( G,Q ); pH 10, 100C, 10 min ( H,R ); pH 10, 90C, 10 min ( I,S ); no AR pretreatment ( J,T ). For MIB 1, the strongest intensity of staining was found in A, B, and G .…”